Danish pharmaceutical company Novo Nordisk announced on Tuesday a strategic partnership with OpenAI to integrate artificial intelligence throughout its operations, including drug discovery, manufacturing, and commercial activities. This move aims to strengthen its position in the competitive weight-loss drug market, where it currently trails behind Eli Lilly.
The collaboration will leverage OpenAI’s advanced technology to analyze complex datasets, identify promising drug candidates, and enhance efficiency in manufacturing, supply chain management, distribution, and corporate functions. While AI is increasingly adopted by drugmakers to simplify routine tasks such as clinical trial recruitment, site selection, and regulatory documentation, industry leaders acknowledge that AI has yet to fully revolutionize the discovery of groundbreaking new molecules.
In a significant development, Novo Nordisk is seeking innovative solutions to reclaim its market share in the obesity drug sector, which is intensifying due to competition from Indianapolis-based Eli Lilly. Lilly recently received US approval for its weight-loss pill Foundayo, following Novo’s launch of oral Wegovy earlier this year. Analysts project that annual revenues from weight-loss medications could surpass $100 billion within the next decade.
The financial details of the Novo-OpenAI agreement were not disclosed. Pilot programs are set to commence across research and development, manufacturing, and commercial operations, with full AI integration expected by the end of 2026. Additionally, OpenAI will assist in training Novo’s global workforce to enhance AI literacy and boost productivity across various departments.
CEO Mike Doustdar emphasized that the partnership aims to augment, not replace, the company’s scientists. He clarified that the initiative is designed to increase productivity and moderate future hiring rather than reduce the current workforce. Doustdar noted that AI will enable employees to work more efficiently, thereby limiting the need for extensive headcount growth. This announcement follows a restructuring last year that resulted in 9,000 job cuts shortly after Doustdar assumed leadership.
OpenAI CEO Sam Altman highlighted the transformative potential of AI in life sciences, stating that it can help people live better and longer lives. He described the collaboration as a means to accelerate scientific discovery, optimize global operations, and reshape patient care.
Furthermore, Novo Nordisk assured that the partnership includes stringent data protection measures, governance protocols, and human oversight. This initiative builds upon the company’s existing AI projects with other technology partners and research institutions.
